SEC Form 4 FORN	14	UNITEI	O STAT	ES S	SECURITIES	S ANI	) E)	CHANG	E CO	OMMIS	SION			
			Washington, D.C. 20549									OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See				NT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person <sup>*</sup> Stelzer Laurie				2. Issuer Name and Ticker or Trading Symbol <u>PMV Pharmaceuticals, Inc.</u> [ PMVP ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
	First)	(Middle)		3. Date <mark>06/08</mark>	e of Earliest Transa /2023	ction (Mo	onth/D	ay/Year)			Officer (give ti below)	tle Othe belo	er (specify w)	
C/O PMV PHARMACEUTICALS, INC. 1 RESEARCH WAY				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indi Line) X	-,			
(Street) PRINCETON	NJ	08540		Dula	1065 1/2)	Trana	+:		<u>tion</u>		Form filed by Person	More than One R	eporting	
(City) (	(State) (Zip)			<ul> <li>Rule 10b5-1(c) Transaction Indication</li> <li>Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.</li> </ul>										
	Ta	able I - Noi	1-Deriva	tive S	ecurities Acq	uired,	Disp	osed of, o	r Bene	eficially	Owned			
Date			2. Transac Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			5. Amount of Securities Beneficially Owned Followin Reported	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	of Indirect	
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
		Table II -	Derivati	ve Se	curities Acqui	red, D	ispo	sed of, or	Benef	icially C	Owned			

(e.g., puts, calls, warrants, options, convertible securities) 6. Date Exercisable and Expiration Date (Month/Day/Year) 8. Price of Derivative 1. Title of Derivative 3. Transaction Date 3A. Deemed Execution Date, 5. Number 9. Number of derivative 11. Nature 7. Title and 10. Ownership 4. Transaction Conversion Amount of of Indirect Beneficial of or Exercise Price of Derivative Securities Underlying Derivative Security Security (Instr. 3) (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 8) Derivative Security (Instr. 5) Securities Beneficially Form: Direct (D) Securities Acquired Ownership Owned or Indirect (Instr. 4) Security (A) or Disposed (Instr. 3 and 4) Following Reported (I) (Instr. 4) of (D) (Instr. 3, 4 and 5) Transaction(s) (Instr. 4) Amount or Number Date Exercisable Expiration Date of Shares Code v (A) (D) Title Stock Option (right to Commor Stock 21,500 \$<mark>5.5</mark>9 06/08/2023 A 21,500 (1) 06/07/2033 \$0.00 21,500 D buy)

Explanation of Responses:

1. Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

Remarks:

## /s/ Winston Kung, by power of 06/12/2023

attorney

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.